Nandrolone / Deca — Injectable AAS

Nandrolone (19-nortestosterone) is a synthetic anabolic-androgenic steroid derived from testosterone by removal of the C19 methyl group. This structural modification produces the 19-nor scaffold, which significantly reduces androgenic potency while preserving anabolic activity — giving nandrolone an anabolic:androgenic ratio of approximately 125:37 compared to testosterone's 100:100 reference standard.

Nandrolone exerts its primary effects through androgen receptor (AR) agonism, similar to testosterone. However, unlike testosterone, nandrolone does not undergo 5α-reduction to a more potent DHT analog — instead, 5α-reduction produces dihydronandrolone, which has significantly weaker AR affinity than nandrolone itself. This explains its comparatively lower androgenicity in tissues rich in 5α-reductase (scalp, skin, prostate).

A critical distinguishing feature is progestin receptor (PR) agonism. Nandrolone and its 5α-reduced metabolite bind progesterone receptors at meaningful affinity, activating progesterone-responsive pathways. This progestin activity is responsible for nandrolone's prolactin-elevating effects — progestin receptor activation in the hypothalamus reduces dopaminergic tone, leading to elevated prolactin secretion from the pituitary.

Aromatization Profile

Nandrolone aromatizes to estradiol at approximately 20% the rate of testosterone. The primary aromatization product is estrone rather than estradiol, making nandrolone's estrogenic activity less potent. However, even modest estradiol elevation can cause gynecomastia when combined with prolactin elevation — a dual estrogenic/prolactin mechanism for nandrolone-associated gynecomastia research.

Nandrolone decanoate has a meaningful clinical research literature, primarily in the context of wasting diseases, renal failure, and osteoporosis. Johansen KL et al. (1999) studied nandrolone decanoate in hemodialysis patients and documented significant gains in fat-free mass and muscle strength. Bhasin S et al. (1997) compared nandrolone with testosterone in HIV-positive men, providing direct comparative data on anabolic and androgenic effects. These clinical datasets remain the primary human evidence base for nandrolone's pharmacological profile, including its distinct progestin activity and prolactin dynamics.

Prolactin is the single most important marker with nandrolone. Baseline prolactin before initiation, then monitoring at 4–6 weeks, is essential. Levels above 25–30 ng/mL (in research contexts) warrant consideration of dopamine agonist co-administration.

Primary / Dose-Dependent

• Prolactin elevation: The most nandrolone-specific adverse effect. Elevated prolactin inhibits dopamine and causes sexual dysfunction, mood dysregulation, potential galactorrhea, and contributes to gynecomastia through dual prolactin/estrogen mechanism.
• HPTA suppression: Among the most potent suppressors of LH/FSH of all AAS. Recovery of HPTA function after nandrolone can be significantly slower than after testosterone — attributed to the long decanoate ester half-life and persistent progestin receptor activity.
• Androgenic effects: Hair loss, acne, and prostate stimulation are less pronounced than testosterone due to weak 5α-reduction product. However, not absent — individual AR sensitivity varies.
• "Deca dick": A colloquial term in the research community describing sexual dysfunction (erectile dysfunction, loss of libido) associated with nandrolone use. Mechanism is multifactorial: suppressed free testosterone, elevated prolactin, and possible CNS dopaminergic effects.

Reported Joint/Connective Tissue Effects

Nandrolone is frequently co-researched with joint health protocols due to anecdotal and some preclinical research suggesting reduced joint pain and improved synovial fluid production. Proposed mechanisms include collagen synthesis stimulation and glucocorticoid receptor antagonism in joint tissue. However, robust controlled clinical data is limited, and these effects are not FDA-approved indications.

• Testosterone (base compound): Almost always co-researched with testosterone as the base to maintain adequate androgenic tone and prevent "Deca dick." The testosterone component provides estrogenic balance the nandrolone cannot fully provide.
• Cabergoline (dopamine agonist): First-line intervention for prolactin elevation from nandrolone. Cabergoline at low doses effectively normalizes prolactin levels by restoring dopaminergic inhibition of pituitary lactotrophs.
• Aromatase inhibitors: Moderate AI use manages the combined estrogenic activity from the testosterone base; nandrolone's low aromatization rarely requires AI intervention alone.
• Trenbolone (stacking 19-nors): Co-administration of two 19-nor compounds (nandrolone + trenbolone) produces additive progestin receptor activation and prolactin elevation — generally avoided in research protocols due to compounded side effect burden.
• BPC-157: Sometimes co-researched given nandrolone's joint research context and BPC-157's documented tendon/ligament healing mechanisms. No known pharmacodynamic conflict.

• Nandrolone decanoate and muscle wasting in HIV patients
  Gold J et al. — International Journal of STD & AIDS (1996). Early clinical research demonstrating anabolic efficacy in wasting conditions. Established nandrolone's FDA-approved indication for anemia of renal disease and bone marrow failure.
• Nandrolone and bone mineral density in postmenopausal women
  Tremollieres F et al. — Maturitas (1992). Documented significant bone density preservation effects, exploring nandrolone's potential in osteoporosis research contexts before estrogen-based HRT dominated.
• Prolactin and sexual dysfunction in nandrolone users
  Pope HG Jr et al. — Biological Psychiatry (2003). Documented endocrine disruption patterns in non-medical AAS users, with nandrolone showing disproportionate prolactin elevation vs other androgens studied.

• Always pair with testosterone: Nandrolone-only protocols cause severe androgenic deficiency due to HPTA suppression without replacement. Testosterone provides the androgenic baseline that nandrolone cannot.
• Monitor prolactin at baseline and 4–6 weeks: Prolactin is the key safety marker for 19-nor compounds. Have cabergoline on hand before beginning any nandrolone protocol.
• Account for long half-life in PCT planning: The decanoate ester's 6–12 day half-life means nandrolone remains active for 3–5 weeks after last injection. SERM-based PCT should begin after adequate clearance — typically 4 weeks post-last injection. HPTA recovery may take significantly longer than after testosterone-only protocols.
• Avoid stacking with trenbolone: Two 19-nor compounds stack their prolactin and progestin receptor burden. If a second compound is desired, use a testosterone-derived compound instead.
• Sexual function monitoring: Any sexual dysfunction onset warrants prolactin lab check before adjusting protocol.